UPCC 10518: An Open Label Single Arm Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post PD 1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma

Enrolling By Invitation
99 years or below
All
Phase 2
10 participants needed
1 Location

Brief description of study

The primary purpose of this study is to gain information about the safety and activity of grapiprant when taken with pembrolizumab in patients who have actively growing or spreading type of advanced stage lung cancer called non-small cell lung cancer (NSCLC).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Non-small Cell Lung Cancer Adenocarcinoma
  • Age: 99 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 831612
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu

 

Interested in the study?

Message For Enrolling By Invitation Trial

study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact a study center.